Hummingbird Bioscience to Present HMBD-802 Antibody-Drug Conjugate at EORTC-NCI-AACR 2024

Hummingbird Bioscience, a company specializing in precision biotherapeutics, has announced it will present a poster on HMBD-802, an innovative dual-payload anti-HER2 antibody-drug conjugate (ADC), at the 36th EORTC-NCI-AACR symposium from October 23 to 25, 2024. This new treatment shows promise for addressing tumors that are resistant to T-DXd, a commonly used therapy, while maintaining a favorable safety profile. Dr. Jerome Boyd-Kirkup, the Chief Scientific Officer of Hummingbird Bioscience, expressed enthusiasm about sharing the potential benefits of HMBD-802 for HER2-positive cancers beyond current treatment options.

The poster presentation is scheduled for October 24, 2024, in the Exhibition Hall, under the session focused on antibody-drug conjugates. The poster is numbered PB154 and carries the abstract number 166. The presentation will cover the significant potential of HMBD-802 in overcoming resistance to topoisomerase 1 inhibitor ADCs, a common challenge in current cancer therapies.

HMBD-802 represents a breakthrough in ADC technology, leveraging Hummingbird Bioscience’s proprietary platforms to deliver targeted treatments to HER2-expressing tumors. This dual-payload ADC aims to enhance anti-tumor efficacy, counteract resistance to existing topoisomerase 1 inhibitors, and minimize systemic toxicity, thereby offering a new therapeutic avenue for patients with difficult-to-treat HER2-positive cancers.

Hummingbird Bioscience focuses on creating transformative biologics to address challenging diseases. The company is developing a range of next-generation ADCs using its proprietary antibody discovery and dual-payload linker platforms. Their pipeline includes various ADCs in preclinical stages and other novel biologics, such as monoclonal antibodies HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb), which are currently in Phase I trials. Additionally, an out-licensed ADC, HMBD-501, is expected to enter clinical trials soon.

The company employs a multidisciplinary approach, integrating computational biology, systems biology, and laboratory research to enhance the efficiency of drug discovery and development. This method helps in identifying targets and selecting the right patients, thereby increasing the success rate and reducing risks associated with new drug development. Hummingbird Bioscience is dedicated to rigorous scientific research, collaboration, and integrity, aiming to expedite the development of new drugs from concept to clinical application.

Overall, Hummingbird Bioscience is leveraging its advanced platforms and integrated research approach to develop new treatments for challenging diseases, with HMBD-802 being a notable example of their innovative work in the field of precision biotherapeutics.